PharVision Advisers’s MaxLinear MXL Stock Holding History

PharVision Advisers’s Portfolio MXL Stock Details MXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,230	Closed	-$213K	–	896
2025 Q3	$213K	Buy	+13,230	New	+$208K	0.12%	463

Other funds holding MXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PharVision Advisers's MXL Position: Q4 2025 in Review

PharVision Advisers sold out of MaxLinear (MXL) in Q4 2025, closing a stake of 13,230 shares — an estimated $213K sold.

PharVision Advisers first reported a position in MXL in Q3 2025 and held it in 1 quarter. The position peaked at $213K in Q3 2025. 240 funds tracked by Wall St. Rank hold MXL as of Q4 2025.

PharVision Advisers reported no remaining MaxLinear position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 13,230 MaxLinear shares in Q4 2025, an estimated $213K.
PharVision Advisers first reported a position in MaxLinear in Q3 2025 and held it in 1 quarter.
PharVision Advisers's MaxLinear position peaked at $213K in Q3 2025.
240 funds tracked by Wall St. Rank held MaxLinear as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.